Impilo has invested in a 29% stake in Cavidi AB, an Uppsala-based diagnostics company focused on HIV Viral Load monitoring. Cavidi has developed a new fully automated viral load diagnostic platform. This platform, Ziva™, aims to meet the need for cost-effective monitoring in high-disease burden countries.
Read moreNews
Impilo Closes €320m Single Asset Continuation Fund Transaction to Support the Continued Growth of Immedica Pharma
On 20th September 2024, Impilo, a Nordic healthcare investment firm and KKR, a leading global investment firm, announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm, focused on the commercialization of medicines for rare diseases and specialty care products.
Impilo and KKR Completes Joint Acquisition of Immedica Pharma
Stockholm and London, 19 September 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products.
Scantox Group acquires Gentronix
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”), well recognized for its high-quality genetic toxicology services and strong scientific engagement.